The value of measuring the level of serum soluble interleukin-2 receptors in lung cancer patients;Wartość oznaczania w surowicy stȩżenia rozpuszczalnych receptorów interleukiny 2 u chorych na raka płuca

Polski Merkuriusz Lekarski

Volumn 16, Issue 92, 2004, Pages 188-190

  Siemińska, Alicja ^a  

^a Klinika Alergologii   (Poland)

Author keywords

Interleukin 2; Interleukin 2 receptor; Lung cancer; Soluble interleukin 2 receptor

Indexed keywords

INTERLEUKIN 2 RECEPTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR; UNCLASSIFIED DRUG;

CANCER GROWTH; DISEASE COURSE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG CANCER; LYMPHOBLAST; REVIEW;

HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTORS, INTERLEUKIN-2; TUMOR MARKERS, BIOLOGICAL;

EID: 1642372105     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Atalas F. i wsp.: Soluble interleukin-2 receptor, Cyfra 21.1 and NSE levels in primary lung cancer. Official Journal of the European Respiratory Society, ERS Anual Congress, Geneva, 1998, P0377.
2. Brunetti G. i wsp.: Soluble interleukin2 receptors (sIL-2R) in monitoring advanced lung cancer during chemotherapy. Lung Cancer, 1999, 23, 1-9.
3. Buccheri G. i wsp.: Soluble interleukin-2 receptor in lung cancer. An indirect marker of tumor activity? Chest, 1991, 99(6), 1433-37.
4. De Vita i wsp.: Analysis of interleukin 2/interleukin-2 receptor system in advanced non-small-cell lung cancer. Tumori, 1998, 84, 33-38.
5. Fischer J. i wsp.: Selective suppression of cytokine secretion in patients with small cell lung cancer. Ann. Oncol., 1995, 9, 921-26.
6. Fischer J. i wsp.: Decrease of Interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer. Ann. Oncol., 1997, 8, 457-61.
7. Flier J., Underhill L.: Cytokine receptors in congenital hematopoietic. N. Engl. J. Med., 1994, 330, 839-46.
8. Katoh R. i wsp.: Changes in serum soluble II-2 receptors (sIL-2R) and immunosupresive acidic protein (IAP) associated with chemotherapy for lung cancer. Anticancer Res., 1997, 17, 3787-92.
9. Kawashima O. i wsp.: The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentration in operable non-small-cell lung cancer patients. Ann. Surg. Oncol., 2000, 7, 239-45.
10. Lissoni P. i wsp.: Serum levels of soluble interleukin-2 recotors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours. Br. J. Cancer, 1989, 60, 616-17.
11. Lissoni P. i wsp.: The biological significance of soluble interleukin-2 receptors in solid tumors. Eur. J. Cancer, 1990, 26, 33-36.
12. Lissoni P. i wsp.: Correlation of serum interleukin-2 receptors and T lymphocyte subsets in cancer patients. Tumori, 1990, 76, 14-17.
13. Lotze M. i wsp.: In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res., 1987, 47, 2188-95.
14. Marino P. i wsp.: Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer. Br. J. Cancer, 1990, 61, 434-35.
15. Miyajima A. i wsp.: Cytokine receptors and signal transduction. Ann. Rev. Immunol., 1992, 10, 295-331.
16. Morgan D., Ruscati F., Gallo R.: Selective in vitro growth of T lymphocytes from normal human bone marrow. Science, 1976, 193, 1007-08.
17. Nelson D.: Soluble interleukin-2 receptors: Analysis in normal individuals and in certain disease states. Fed. Proc., 1986, 45, 377-83.
18. Orditura M. i wsp.: Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors. Int. J. Mol. Med., 1998, 2, 75-79.
19. Orson F. i wsp.: Interleukin 2 receptor expression by cells in human aging. Cell Immunol., 1989, 124, 278-91.
20. Pizzolo G. i wsp.: Soluble interleukin-2 receptors in serum of patients with Hodgkin's disease. Br. J. Cancer, 1987, 55, 427-28.
21. Poulakis N. i wsp.: Soluble interleukin-2 receptors and other markers in primary lung cancer. Cancer, 1991, 68(5), 1045-49.
22. Rubin L., Jay G., Nelson D.: The released interleukin-2 receptor binds interleukin-2 efficiently. J. Immunol., 1986, 137, 3841-44.
23. Rubin L., Nelson D.: The soluble interleukin-2 receptor: biology, function, and clinical application. Ann. Intern. Med., 1990, 113, 619-24.
24. Saadeh C. i wsp.: Sera from the aged contain higher levels of IL-2 receptors compared to young adults. Fed. Proc., 1986, 45, 371-78.
25. Sarandakau A. i wsp.: Soluble interleukin 2 receptors (sIL-2R) and neuron specific enolase (NSE) in small cell lung carcinoma. Anticancer Res., 1993, 13, 173-75.
26. Schirrmacher V. i wsp.: Determination of cell-free interleukin-2 receptor level in the serum of normal animals and of animals bearing IL-2 receptor positive tumours with high or low metastatic capacity. Br. J. Cancer, 1987, 55, 583-87.
27. Semenzato G. i wsp.: High serum levels soluble interleukin-2 receptors in sarcoidosis. Sarcoidosis, 1987, 4, 25-27.
28. Smith K.A.: Interleukin-2: inception, impact, and implications. Science, 1988, 240, 1169-76.
29. Sugarman B.J., Lewis G., Eessalu T.: Effects of growth factors on the antiproliferative activity of tumor necrosis factor. Cancer Res., 1987, 47, 480-84.
30. Taniguchi T., Minami Y.: The IL-2/IL-2 receptor system: a current overview. Cell, 1993, 73, 5-8.
31. Tisi E.: Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer, 1992, 69(10), 2458-62.
32. Wagner D.: Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: Correlation with survival. J. Clin. Oncol., 1987, 5, 1262-74.
33. Yano T. i wsp.: The clinical significance of serum soluble interleukin-2 receptors in lung cancer. Lung Cancer, 1996, 15, 79-84.
34. Yano T. i wsp.: Interleukin-2 receptors in pulmonary adenocarcinoma tissue. Lung Cancer 1996, 16, 13-19.